Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT).
Elisabetta ParisiDonatella ArpaGiulia GhigiLucia FabbriFlavia FocaLuca TontiniElisa NeriMartina PieriSimona CimaMarco Angelo BurgioMaria Luisa BelliLuca LuzziAntonino RomeoPublished in: Cancers (2023)
Malignant Pleural Mesothelioma (MPM) is a rare malignancy with an overall poor prognosis. The standard therapeutic strategy in early-stage disease is trimodality therapy. In this publication, we report the preliminary toxicity results of the first 20 patients treated with accelerated hypofractionated radiotherapy. Between July 2017 to June 2019, 20 MPM patients were enrolled and treated with accelerated hypofractionated radiotherapy using helical tomotherapy and intensity-modulated arc therapy. The prescription dose was 30 Gy in five daily fractions, while an inhomogeneous dose escalation to 40 Gy was prescribed based solely upon the presence of gross residual tumor. Only one case of G3 toxicity was reported, which was a bilateral pneumonitis that occurred two years after treatment probably due to superinfection. Median Time to Progression reached 18.2 months while one- and three-year Overall Survival rates were 85% (95% CI:60.4-94.9) and 49.5% (95% CI:26.5-68.9), respectively. Treatment of the intact lung with pleural intensity-modulated arc irradiation is a novel treatment strategy that appears to be safe, feasible, and without a high grade of lung toxicity. Survival rates and Time to Progression are encouraging.
Keyphrases
- early stage
- poor prognosis
- radiation therapy
- oxidative stress
- high grade
- radiation induced
- locally advanced
- end stage renal disease
- long non coding rna
- newly diagnosed
- ejection fraction
- physical activity
- clinical trial
- prognostic factors
- squamous cell carcinoma
- peritoneal dialysis
- open label
- study protocol
- systemic sclerosis
- small cell lung cancer
- interstitial lung disease
- mesenchymal stem cells
- bone marrow
- case report
- phase iii
- double blind